What the obstetrician does have is the freedom of choice to make decisions when he is confident that the quality of neonatal care will be excellent, however small the baby. This need not and must not be the sole prerogative of obstetricians in regional centres. Even if there were several perinatal centres in each region they would not be likely to cope with all or even most of the high-risk pregnancies presenting at district maternity hospitals. Uncritical expansion of antenatal referral services erodes the experience of medical and nursing staff in the management of common pregnancy complications-yet at the same time accommodation for such patients at the regional centre can never be guaranteed.
There would be little justification for the transfer of premature babies who are not suffering from respiratory failure and for many examples of antenatal referral if the standards of neonatal care in district maternity hospitals were improved. The essential neonatal facilities that must be maintained in district maternity hospitals can be spelt out: constantly available skilled resuscitation and short-term ventilatory support; the ability to anticipate neonatal problems and recognise them early; reliable monitoring for and prophylaxis against apnoeic attacks; scrupulous control of oxygen treatment in babies with respiratory distress; awareness of the individual baby's thermal homoeostasis; and a critical approach to gavage feeding in small babies. The provision of such basic care is not costly, and it is to midwives and nurses we must turn to maintain these standards. An increase in their numbers is certainly necessary in most district maternity hospitals, but ensuring that existing staff are appropriately trained is just as important. Present training programmes, in their attempt to be comprehensive, frequently fail to teach the nuances of neonatal care. Yet in this specialty it is often nuances that dictate the difference between appropriate and poor care.
We have reached a crossroads in the regional organisation of perinatal care in Britain. Our We ought not to be over anxious to encourage innovation in cases of doubtful improvement, for an old system must ever have advantages over a new one: it is established and understood. C C Colton 1825.
A preparation of timolol maleate for topical use was released in Britain in January 1979. By December 1981, 50 000 patients with glaucoma were thought to be receiving treatment with this drug. We need, therefore, to review the action of beta-blockers in glaucomatous eyes, to emphasise possible unwanted effects, and to try to identify the place of these drugs in the management of chronic simple glaucoma.
Chronic simple glaucoma is a disease treated in the main by topically applied drugs which lower the intraocular pressure. The side effects on the eye of long-term drug administration include blurred vision, irritation, and pain-and since the disease itself is largely asymptomatic except in the late stages, the side effects discourage patients from taking their drugs regularly. The results are poor control of the intraocular pressure' 2 and progression of the disease. Against that background there has been a great need for a tolerable, effective drug for glaucoma that can be administered topically.
It is now nearly 14 years since the first report of the effect of intravenous and oral propranolol on the intraocular pressure.3 This and other beta-blockers have had their ocular hypotensive effect confirmed both when given by mouth and when applied topically.4 5 Not until the advent of timolol, however, did the pharmaceutical industry come up with an acceptable combination of hypotensive effect, duration of action, and relative freedom from local side effects.
Timolol is a beta,-adrenergic and beta2-adrenergic blocker which has neither any intrinsic sympathomimetic action nor any important local anaesthetic properties. Each 1 ml of 0*25% solution contains 0*34 mg timolol maleate, and the drug is given twice daily. 6 The initial clinical studies6 I and later clinical trials have shown that the hypotensive effect compares favourably with that of pilocarpine8 and adrenaline,9 while adding timolol to "maximum medical therapy" further lowers intraocular pressure.10 This additive effect is seen with both pilocarpine and acetazolamide but is less certain for combinations of adrenaline and timolol."1-'4 Long-term studies have shown that the hypotensive effect is maintained for years, though some patients develop tolerance and in them the hypotensive effect may be reduced by up to 250 / after one or more months of use. 15 Local side effects remain remarkably few. No patient has developed the ocular syndrome seen with oral practolol. A few patients have complained of pain and blurred vision, while punctate keratitis and corneal anaesthesia have been seen on rare occasions.16 Systemic side effects appear more common; these are due to absorption of the drug through the nasal mucosa, which allows 80% of the total dose to pass directly into the circulation without deactivation by the liver.'7 Systemic side effects reported in one 1 1-month study included depression, anxiety, and confusional states.'6 Bradycardia (affecting both resting and exercise rates), arrhythmias, and airways obstruction have also been reported.'6 18 Timolol should not be used in known asthmatics or in patients with any form of reversible airways obstruction. Similarly it should be given with caution in patients with known heart disease.
What, then, does the future hold for beta-blockers in eye disease? The twice-a-day regimen is probably optimum, frequent enough for the patient to remember it but not so frequent as to be a burden. The hypotensive effect may not be improved on. Nevertheless, the ocular penetration of timolol is much less than that of other topically applied beta-blockers. 19 Any increase in penetration (for example, development of prodrug such as dipivalyl adrenaline-converted to adrenaline within the eye)20 might allow a lower total dose to be given to achieve the same hypotensive effect with a reduction in the systemic side effects. Even without these possible improvements, however, the advent of topical beta-blockers in general and timolol in particular must be seen as a major advance in the medical treatment of chronic simple glaucoma. They are likely to be responsible, along with laser surgery and better techniques for conventional glaucoma surgery, for a major realignment of ophthalmic ideas in the management of this disease. ROGER 
